NDA 216632 · Bausch
Cabtreo
Adapalene, Benzoyl Peroxide, Clindamycin Phosphate · Topical · Retinoid
Last checked: Nov 20, 2026Latest source record: Oct 20, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 20, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
112
28 Phase 3, 7 recruiting
FAERS reports
60
8 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 24, 2025.
CABTREO is indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older. CABTREO is a combination of clindamycin phosphate (a lincosamide antibacterial), adapalene (a retinoid), and benzoyl peroxide indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older. ( 1 )
Mechanism: Clindamycin: Clindamycin is a lincosamide antibacterial [see Microbiology ( 12.4 )] . Adapalene: Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown. Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic...
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CABTREO · ADAPALENE 0.15%; BENZOYL PEROXIDE 3.1%; CLINDAMYCIN PHOSPHATE 1.2% · GEL, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Adapalene" as an intervention, any sponsor and status, largest first.
- Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01742637 · 2,008 participants · Start Oct 2012 · Primary completion Feb 2014
Drug: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%; Epiduo® Gel and 1 more · For: Acne Vulgaris
- A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT00421993 · 1,670 participants · Start Oct 2006 · Primary completion Oct 2007
Drug: Adapalene/Benzoyl Peroxide; Adapalene and 2 more · For: Acne Vulgaris
Sites: Huntsville, Alabama; Little Rock, Arkansas; Fresno, California · 62 sites in all
- Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT00422240 · 1,668 participants · Start Jun 27, 2006 · Primary completion Jul 12, 2007
Drug: Adapalene/Benzoyl Peroxide; Adapalene Gel, 0.1% and 2 more · For: Acne Vulgaris
Sites: San Antonio, Texas
- A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne VulgarisPivotal-lookingCompleted
Lee's Pharmaceutical LimitedIndustry
NCT03615768 · 1,617 participants · Start Aug 14, 2018 · Primary completion Feb 13, 2020
Drug: Adapalene Gel; Clindamycin Gel · For: Acne Vulgaris
Sites: Nanjing, China
- Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical GelPivotal-lookingCompleted
Actavis Mid-Atlantic LLCIndustry
NCT01095640 · 1,159 participants · Start Mar 2009 · Primary completion Dec 2009
Drug: adapalene 0.3% topical gel · For: Acne Vulgaris
Sites: Mumbai, India
- Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%Pivotal-lookingCompleted
Galderma R&DIndustry
NCT00598832 · 1,075 participants · Start Nov 2007 · Primary completion Oct 2008
Drug: Adapalene lotion 0.1%; Adapalene Lotion Vehicle · For: Acne Vulgaris
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; Marina del Rey, California · 34 sites in all
- Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%Pivotal-lookingCompleted
Galderma R&DIndustry
NCT00599521 · 1,067 participants · Start Nov 2007 · Primary completion Nov 2008
Drug: Adapalene lotion 0.1%; Adapalene Lotion Vehicle · For: Acne Vulgaris
Sites: San Diego, California; Vista, California; Denver, Colorado · 34 sites in all
- Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne VulgarisPivotal-lookingCompleted
Actavis Inc.Industry
NCT02651220 · 1,001 participants · Start Nov 2015 · Primary completion Apr 2016
Drug: Epiduo® Forte Gel; Adapalene and Benzoyl Peroxide Gel and 1 more · For: Acne
Sites: Mesa, Arizona; Tucson, Arizona; Anaheim, California · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- application site pain7
- drug hypersensitivity6
- application site dryness5
- drug ineffective5
- application site pruritus4
- application site erythema3
- erythema3
- hypersensitivity3
- pain3
- product use issue3
- pruritus3
- accidental exposure to product2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 14 |
| 2025 | 31 |
| 2026 | 15 |
Recalls
1 FDA enforcement reports for this application.
Feb 12, 2024 · Class II · Terminated
CGMP Deviations: Product was stored outside labeled storage temperature requirements. Product was exposed to controlled room temperature environment instead of remaining refrigerated.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cabtreo (Adapalene/Benzoyl/Clindamycin)
2024 spending
$197K
Beneficiaries
125
210 claims
Per beneficiary
$1,572
$18.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $196,507 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Perioral dermatitis: Diagnosis, proposed etiologies, and management.
Searle T, Ali FR, Al-Niaimi F · J Cosmet Dermatol 2021 · Systematic Review
- Topical Retinoids in Acne Vulgaris: A Systematic Review.
Kolli SS, Pecone D, Pona A, et al. · Am J Clin Dermatol 2019 · Systematic Review
- Acne vulgaris.
Purdy S, Deberker D · BMJ Clin Evid 2008 · Systematic Review
- Acne vulgaris.
Purdy S, de Berker D · BMJ Clin Evid 2011 · Systematic Review
- Application Characteristics and Patient Preference of Triple-Combination vs Layered Topicals for Acne: Split-Face Study.
Draelos ZD · J Drugs Dermatol 2024 · Comparative Study, Randomized Controlled Trial
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.